{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-109976","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.573283+00:00","generated_at":"2026-05-23T00:49:09.922160+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics to cut 45% of workforce; CLO Mike Ouimette departs","bullets":["Reduction impacts ~45% of current employees; expected to substantially complete by end of Q2 2025.","Total severance and related benefits estimated at $3.6M, primarily one-time cash termination benefits.","Mike Ouimette, Chief Legal and Compliance Officer and Corporate Secretary, terminated effective May 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-109976","json":"https://secwatch.observer/filing/0001193125-25-109976.json","markdown":"https://secwatch.observer/filing/0001193125-25-109976.md","text":"https://secwatch.observer/filing/0001193125-25-109976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/d949809d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:49:09.922160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31228ab773","claim":"Mike Ouimette was terminated as Chief Legal and Compliance Officer and Corporate Secretary at PLIANT THERAPEUTICS, INC..","evidence_excerpt":"On May 1, 2025, the Company announced that in connection with the workforce reduction, the employment of Mike Ouimette, the Company’s Chief Legal and Compliance Officer and Corporate Secretary, would terminate effective May 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Legal and Compliance Officer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"49a9fee368f4ca8007271a8eebc7aa9707e94d8a","claim":"PLIANT THERAPEUTICS, INC. announced a restructuring with charges of $3.6 million (approximately 45% of its current employees).","evidence_excerpt":"current employees. The Company expects to substantially complete the workforce reduction by the end of the second quarter of 2025. The Company expects to recognize approximately $3.6 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$3.6 million"},{"label":"Headcount","value":"approximately 45% of its current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}